Patent Case Watch

Patent opinions from the Eastern District of Texas and the U.S. Court of Appeals for the Federal Circuit

Fed. Cir.

AbbVie Inc. v. Kennedy Inst. of Rheumatology, No. 13-1545 (Fed. Cir. Aug. 21, 2014)

Affirmed
Invalidity (§ 102/§ 103)
Court
U.S. Court of Appeals for the Federal Circuit
Case No.
No. 13-1545
Decided
August 21, 2014
Judge
Dyk, J.
Document
Precedential Opinion
Length
28 pages

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

The Mathilda and Terrance Kennedy Institute of Rheumatology Trust (Kennedy) owns U.S. Patent Nos. 7,846,442 (the ’442 patent) and 6,270,766 (the ’766 p a- tent). Both patents are directed towards methods of treating rheumatoid arthritis by co -administering two drugs. AbbVie, Inc. and AbbVie Biotechnology Ltd. (collec- tively, AbbVie) are licensees of the ’766 patent but not the ’442 patent.

Download Opinion (PDF)

Source: govinfo.gov USCOURTS collection · retrieved July 23, 2026 · Report an error